OCCIDENT () Overview

  • Investor Type
  • Family Office

  • Status
  • Active

  • Professionals
  • 7

Professionals

  • Investments
  • 42

  • Portfolio
  • 17

  • Exits
  • 11

Exits

OCCIDENT () General Information

Company Description

Founded in 2012, OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, the firm supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards and accompanies their portfolio companies over the long term both financially as well as with their extensive experience. The firm invests its own money and makes decisions.

Business Details

Formerly Known As
Occident Group
Year Founded
2012
Investor Status
Actively Seeking New Investments
Trade Association
Swiss Private Equity & Corporate Finance (SWPE)
Primary Investor Type
Family Office
Other Investor Types
Venture Capital
Corporate Office
  • Klenzestrasse 22
  • 80469 Munich
  • Germany
+49 089

OCCIDENT () Investments (42)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Immitra Bio 21-Jul-2026 Early Stage VC Drug Discovery Pre-Clinical Trials
Hemotune 01-Dec-2025 Therapeutic Devices Startup
Tubulis 15-Oct-2025 Drug Discovery Clinical Trials - Phase 2
EBAMed 24-Jan-2025 Diagnostic Equipment Generating Revenue
Lymphatica Medtech 08-Oct-2024 Therapeutic Devices Generating Revenue
Tubulis 14-Mar-2024 Drug Discovery Clinical Trials - Phase 2
Altavo 01-Feb-2024 Therapeutic Devices Generating Revenue
Chipmetrics 24-Jan-2024 Application Specific Semiconductors Generating Revenue
ReCatalyst 12-Jul-2023 Seed Round Alternative Energy Equipment Generating Revenue
iMusician 03-May-2023 PE Growth/Expansion Media and Information Services (B2B) Generating Revenue
You’re viewing 10 of 42 investments. Get the full list »

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OCCIDENT () Exits (11)

Company Name Exit Date Exit Type Exit Size
Tubulis 21-May-2026 Merger/Acquisition
iThera Medical 11-May-2026
Invasight 24-Oct-2025
mk2 Biotechnologies 03-Feb-2025
Lunaphore 07-Jul-2023
Adivo 07-Jun-2023
Versantis 29-Sep-2022
GNA Biosolutions 05-Feb-2021
Cunesoft 08-Jan-2020 Buyout/LBO
kooaba 14-Jan-2014 Merger/Acquisition
You’re viewing 10 of 11 exits. Get the full list »

OCCIDENT () Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

OCCIDENT () FAQs

  • What is OCCIDENT ()?

    Founded in 2012, OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today.

  • When was OCCIDENT () founded?

    OCCIDENT () was founded in 2012.

  • Where is OCCIDENT () headquartered?

    OCCIDENT () is headquartered in Munich, Germany.

  • How many investments has OCCIDENT () made?

    OCCIDENT () has made 42 investments.

  • What has OCCIDENT () invested in?

    OCCIDENT () has made numerous investments in companies like Immitra Bio, Hemotune, and Tubulis within the Drug Discovery and Therapeutic Devices industries.

  • What has OCCIDENT () invested in recently?

    OCCIDENT ()'s latest investment was on 21-Jul-2026 in Immitra Bio, a company within the Drug Discovery industry.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process